Welcome Yanbo Fan, PhD!
Effective 10/15/19: Dr. Yanbo Fan will join the University of Cincinnati as an assistant professor in the Department of Cancer Biology. Dr. Fan’s research will focus on defining the role of transcription factor EB (TFEB), a master regulatory gene for autophagy and lysosome biogenesis, in vascular endothelial and smooth muscle cells important for angiogenesis, cancer metastasis, aneurysm and other vascular and metabolic diseases.
Congratulations to Xiaoting Zhang, PhD!
Dr. Zhang, Cancer Biology professor, has been awarded his second NIH R01 from the National Cancer Institute. The five year grant entitled “Small RNAs in Breast Cancer Metastasis” will focus on the regulation and function of a key tissue-specific estrogen receptor coactivator MED1 and its upstream and downstream small RNA pathways in breast cancer.
Congratulations to JJ Diao, PhD!
Dr. Diao, Cancer Biology assistant professor, has been awarded an NIH R21 from the National Institute on Aging. The two year grant entitled “Single-molecule study of alpha-synuclein” will focus on multiple single-molecule/single-particle biophysical and biochemical assays used to characterize the oligomerization and function of α-synuclein in membrane environments mimicking presynaptic terminals.
Congratulations to Maria Czyzyk-Krzeska, PhD!
Dr. Czyzyk-Krzeska, Cancer Biology professor, has been awarded an NIH R01 from the National Institute of General Medical Sciences. The four year grant entitled “Mechanisms of selective autophagy” will focus on a novel, selective, human-specific autophagy downstream from the von Hippel Lindau tumor suppressor gene; a pathway that is regulated by several non-canonical regulators and targets for degradation oncogenic cargo.
Promotion to Professor for Xiaoting Zhang, PhD
On September 1, 2019, Xiaoting Zhang, PhD, in the department of Cancer Biology was promoted to Professor. Congratulations Dr. Zhang!
Congratulations to Chunying Du, PhD!
Dr. Du, Cancer Biology associate professor, has been awarded an NIH R21 from the National Cancer Institute. The two year grant entitled “Novel Targeting of Liver Cancer Deficient of DNA Repair” will focus on a DNA damage repair mechanism underlying the development of the most common form of malignancy in the liver - hepatocellular carcinoma (HCC) - by loss of the new HCC suppressor BRUCE.